Bayer Signs a Three Year Multi Target AI-based Agreement with Exscientia to Treat Cardiovascular and Oncology Diseases
Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer
Shots:
- Exscientia to get up to $266.2M including upfront, research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration
- The partners will focus on early research projects combining Exscientia’s AI drug discovery platform and drug design know-how with Bayer’s data and drug discovery capabilities for the identification of therapies for cardiovascular and oncological diseases
- Exscientia’s AI-driven drug discovery platform providing novel chemical matter for targets and enables identification of therapies
Click here to read full press release/ article | Ref: Bayer | Image: Behance